An Act To Amend Maine'S Prescription Drug Labeling Law By Allowing The Removal Of The Name Of A Prescriber Of Mifepristone, Misoprostol And Their Generic Alternatives

132nd Legislature (2025-2026) Introduced by Donna Bailey and 9 co-sponsors

Allows pharmacies to omit the prescriber's name from labels for mifepristone, misoprostol, and generics, affecting patient labels while preserving prescribing authority.

Signed by Governor

#labeling #prescriptiondrugs #regulation

LD 538 — Summary

Title: An Act To Amend Maine's Prescription Drug Labeling Law By Allowing The Removal Of The Name Of A Prescriber Of Mifepristone, Misoprostol And Their Generic Alternatives
Bill number: LD 538
Sponsor: Rep. Cluchey of Bowdoinham
Committee: Health Coverage, Insurance and Financial Services
Introduced: February 11, 2025
Status: Passed and signed by the Governor (May 29, 2025) — enacted as amended (Committee Amendment "A" H‑179)

Purpose / Intent

LD 538 modifies Maine’s prescription drug labeling requirements to permit the removal of the prescriber’s name from the pharmacy label for prescriptions of mifepristone, misoprostol, and their generic equivalents. The change is limited to the labeling information displayed on the prescription container/label.

Key provisions

Allows pharmacies to omit the prescriber’s name from the prescription label for the drugs mifepristone and misoprostol and their generic alternatives.

The enacted version is the bill as engrossed with Committee Amendment "A" (H‑179). (Text of the amendment is not included in the available materials.)

Does not alter prescribing authority, the legal status of the prescriptions themselves, or other dispensing requirements except as they relate specifically to the presence of the prescriber’s name on the label.

Who is affected

Patients receiving mifepristone, misoprostol, or their generics — their prescription labels may no longer display the prescriber’s name.

Pharmacists and pharmacy operations — may change label-generation practices and pharmacy workflow to accommodate optional omission of prescriber names.

Prescribers of those medications — their names may be omitted from patient-facing labels, which could affect visibility of who issued the prescription.

Regulators and enforcement entities — will administer and monitor compliance with the revised labeling standard.

Procedural/timeline notes

Referred to and reviewed by the Committee on Health Coverage, Insurance and Financial Services; work session held March 26, 2025.

Committee reported out as OTP‑AM (majority ought to pass as amended); Committee Amendment "A" (H‑179) was adopted.

House vote (May 20, 2025): 75–71 (close vote) to pass as amended. Senate adoption and concurrence followed; final passage to be enacted May 27, 2025.

Signed by the Governor on May 29, 2025.

Caveats / additional information

This summary is based on legislative actions, fiscal notes, and bill metadata; the full statutory language and Committee Amendment text were not provided here. For specific operational, compliance, or legal interpretations, review the enacted statutory language and any implementing guidance from state agencies.

Bill